ReviewIBRO neuroscience reports2026
Neuroendocrine regulation of appetite and energy balance in metabolic disorders.
Review in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The physiological control mechanisms that govern appetite and energy balance function through neuroendocrine systems that link central nervous system functions to peripheral organ activities and hormonal distribution pathways. The hypothalamus operates as the main control center, which processes metabolic information from hormones like leptin, insulin, ghrelin, and gut-derived peptides to govern both eating and energy use. People consume food through homeostatic processes, which control appetite together with non-homeostatic processes, which include reward pathways and circadian rhythms. The body develops metabolic disorders like obesity, type 2 diabetes, and cachexia because these systems experience dysregulation. Central-peripheral communication breakdowns occur because of chronic energy surplus and inflammation, together with hormonal resistance. People establish their feeding behavior patterns through reward-related dopaminergic signaling, circadian misalignment, and sex hormone fluctuations. Researchers have discovered that neuroinflammation, genetic, epigenetic factors, and newly identified neuropeptides all contribute to the metabolic diseases that they study. Therapeutic strategies that target neuroendocrine pathways, which include GLP-1 receptor agonists, melanocortin receptor agonists, and bariatric surgery, demonstrate potential to restore appetite control and enhance metabolic health. This study explains how neuroendocrine systems control appetite and how metabolic disorders disrupt these regulatory processes while identifying new therapeutic possibilities and future research needs in metabolic neuroscience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.